Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2467${count})

  • Rapid Response Innovation Awards, 2008
    MicroRNA regulation of aSynuclein as a drug target

    Objective/Rationale:
    A central hypothesis for Parkinson’s pathology is that excessive alpha-Synuclein protein, most likely in the form of aggregates, is toxic to midbrain dopamine neurons. Our prior...

  • Rapid Response Innovation Awards, 2008
    Evaluation of a Novel Non-coding Viral RNA to Prevent Neurodegeneration

    Objective/Rationale:
    Viruses need to keep cells alive during the course of their infection. We recently identified a novel viral RNA which does not code for any known protein but efficiently stops...

  • MJFF Research Grant, 2008
    Wearable Sensors and a Web-Based Application to Monitor Patients with Parkinson's Disease in the Home Environment

    Objective/Rationale:
    Critical research roadblocks hinder our ability to identify genetic and environmental causes of Parkinson’s disease and to develop novel, transformative therapies for Parkinson’s...

  • Target Validation, 2008
    Evaluation of the striatum-enriched genes, CalDAG-GEF1 and CalDAG-GEF2, as targets for the treatment and prevention of L-DOPA induced dyskinesias

    Objective/Rationale:
    The most widely prescribed therapy for Parkinson’s disease is levodopa (L-DOPA), which allows patients to regain motor control. However, many patients develop adverse reactions to...

  • Target Validation, 2008
    CaMKII as a Therapeutic Target in Parkinson's Disease

    Objective/Rationale:

    Neurons in the striatum play a critical role in the fine control of movements. The primary loss of dopamine neurons in Parkinson's Disease induces dramatic secondary changes in the...

  • Target Validation, 2008
    Hsp90 as a Target for Neuroprotective Agents in Parkinson's Disease

    Objective/Rationale: 
    Cell death caused by alpha-synuclein aggregation is thought to play a central role in the pathogenesis of Parkinson’s disease. Previous studies have found that a class of...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.